Interferon Sensitivity-determining Region of Hepatitis C Virus Influences Virus Production and Interferon Signaling

Overview

Journal Oncotarget

Specialty Oncology

Date 2018 Feb 22

PMID 29464023

Citations 3

Authors

Ryuichi Sugiyama

Asako Murayama

Sayuri Nitta

Norie Yamada

Megumi Tasaka-Fujita

Takahiro Masaki

Hussein Hassan Aly

Masaaki Shiina

Akihide Ryo

Koji Ishii

Takaji Wakita

Takanobu Kato

Affiliations

Soon will be listed here.

Abstract

The number of amino acid substitutions in the interferon (IFN) sensitivity-determining region (ISDR) of hepatitis C virus (HCV) NS5A is a strong predictor for the outcome of IFN-based treatment. To assess the involvement of ISDR in the HCV life cycle and to clarify the molecular mechanisms influencing IFN susceptibility, we used recombinant JFH-1 viruses with NS5A of the genotype 1b Con1 strain (JFH1/5ACon1) and with NS5A ISDR containing 7 amino acid substitutions (JFH1/5ACon1/i-7mut), and compared the virus propagation and the induction of interferon-stimulated genes (ISGs). By transfecting RNAs of these strains into HuH-7-derived cells, we found that the efficiency of infectious virus production of JFH1/5ACon1/i-7mut was attenuated compared with JFH1/5ACon1. After transfecting full-length HCV RNA into HepaRG cells, the mRNA expression of ISGs was sufficiently induced by IFN treatment in JFH1/5ACon1/i-7mut-transfected but not in JFH1/5ACon1-transfected cells. These data suggested that the NS5A-mediated inhibition of ISG induction was deteriorated by amino acid substitutions in the ISDR. In conclusion, using recombinant JFH-1 viruses, we demonstrated that HCV NS5A is associated with infectious virus production and the inhibition of IFN signaling, and amino acid substitutions in the NS5A ISDR deteriorate these functions. These observations explain the strain-specific evasion of IFN signaling by HCV.

Citing Articles

Suppression of Innate Immunity by the Hepatitis C Virus (HCV): Revisiting the Specificity of Host-Virus Interactive Pathways.

Barik S Int J Mol Sci. 2023; 24(22).

PMID: 38003289 PMC: 10671098. DOI: 10.3390/ijms242216100.

Baseline Amino Acid Substitutions in the NS5A ISDR and PKR Binding Domain of Hepatitis C and Different Fibrosis Levels and Levels of Development of Hepatocellular Carcinoma in Patients Treated with DAAs.

Paolucci S, Piralla A, Novazzi F, Fratini A, Maserati R, Gulminetti R Viruses. 2020; 12(3).

PMID: 32106574 PMC: 7150791. DOI: 10.3390/v12030255.

Manipulation of Type I Interferon Signaling by HIV and AIDS-Associated Viruses.

He B, Tran J, Sanchez D J Immunol Res. 2019; 2019:8685312.

PMID: 31089479 PMC: 6476103. DOI: 10.1155/2019/8685312.

References

Kurosaki M, Enomoto N, Murakami T, Sakuma I, Asahina Y, Yamamoto C . Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy. Hepatology. 1997; 25(3):750-3. DOI: 10.1002/hep.510250343. View

Tellinghuisen T, Marcotrigiano J, Rice C . Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature. 2005; 435(7040):374-9. PMC: 1440517. DOI: 10.1038/nature03580. View

Masaki T, Matsunaga S, Takahashi H, Nakashima K, Kimura Y, Ito M . Involvement of hepatitis C virus NS5A hyperphosphorylation mediated by casein kinase I-α in infectious virus production. J Virol. 2014; 88(13):7541-55. PMC: 4054430. DOI: 10.1128/JVI.03170-13. View

Miyanari Y, Hijikata M, Yamaji M, Hosaka M, Takahashi H, Shimotohno K . Hepatitis C virus non-structural proteins in the probable membranous compartment function in viral genome replication. J Biol Chem. 2003; 278(50):50301-8. DOI: 10.1074/jbc.M305684200. View

Kato T, Date T, Murayama A, Morikawa K, Akazawa D, Wakita T . Cell culture and infection system for hepatitis C virus. Nat Protoc. 2007; 1(5):2334-9. DOI: 10.1038/nprot.2006.395. View

Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C . Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 1996; 334(2):77-81. DOI: 10.1056/NEJM199601113340203. View

Murayama A, Sugiyama N, Yoshimura S, Ishihara-Sugano M, Masaki T, Kim S . A subclone of HuH-7 with enhanced intracellular hepatitis C virus production and evasion of virus related-cell cycle arrest. PLoS One. 2013; 7(12):e52697. PMC: 3527576. DOI: 10.1371/journal.pone.0052697. View

Masaki T, Suzuki R, Murakami K, Aizaki H, Ishii K, Murayama A . Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. J Virol. 2008; 82(16):7964-76. PMC: 2519576. DOI: 10.1128/JVI.00826-08. View

Nitta S, Asahina Y, Matsuda M, Yamada N, Sugiyama R, Masaki T . Effects of Resistance-Associated NS5A Mutations in Hepatitis C Virus on Viral Production and Susceptibility to Antiviral Reagents. Sci Rep. 2016; 6:34652. PMC: 5050404. DOI: 10.1038/srep34652. View

10.

Okamoto Y, Masaki T, Murayama A, Munakata T, Nomoto A, Nakamoto S . Development of recombinant hepatitis C virus with NS5A from strains of genotypes 1 and 2. Biochem Biophys Res Commun. 2011; 410(3):404-9. DOI: 10.1016/j.bbrc.2011.05.144. View

11.

Ghany M, Strader D, Thomas D, Seeff L . Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009; 49(4):1335-74. PMC: 7477893. DOI: 10.1002/hep.22759. View

12.

Feld J, Liang T . Hepatitis C -- identifying patients with progressive liver injury. Hepatology. 2006; 43(2 Suppl 1):S194-206. DOI: 10.1002/hep.21065. View

13.

Lan K, Lan K, Lee W, Sheu M, Chen M, Lee Y . HCV NS5A inhibits interferon-alpha signaling through suppression of STAT1 phosphorylation in hepatocyte-derived cell lines. J Hepatol. 2007; 46(5):759-67. DOI: 10.1016/j.jhep.2006.11.013. View

14.

Grakoui A, Wychowski C, Lin C, Feinstone S, Rice C . Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol. 1993; 67(3):1385-95. PMC: 237508. DOI: 10.1128/JVI.67.3.1385-1395.1993. View

15.

Hiraga N, Abe H, Imamura M, Tsuge M, Takahashi S, Hayes C . Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus. Hepatology. 2011; 54(3):764-71. DOI: 10.1002/hep.24453. View

16.

Huang L, Hwang J, Sharma S, Hargittai M, Chen Y, Arnold J . Hepatitis C virus nonstructural protein 5A (NS5A) is an RNA-binding protein. J Biol Chem. 2005; 280(43):36417-28. DOI: 10.1074/jbc.M508175200. View

17.

Sumpter Jr R, Loo Y, Foy E, Li K, Yoneyama M, Fujita T . Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol. 2005; 79(5):2689-99. PMC: 548482. DOI: 10.1128/JVI.79.5.2689-2699.2005. View

18.

Gong G, Cao J, Jiang Y, Zhou Y, Liu B . Hepatitis C virus non-structural 5A abrogates signal transducer and activator of transcription-1 nuclear translocation induced by IFN-alpha through dephosphorylation. World J Gastroenterol. 2007; 13(30):4080-4. PMC: 4205308. DOI: 10.3748/wjg.v13.i30.4080. View

19.

Murayama A, Sugiyama N, Watashi K, Masaki T, Suzuki R, Aizaki H . Japanese reference panel of blood specimens for evaluation of hepatitis C virus RNA and core antigen quantitative assays. J Clin Microbiol. 2012; 50(6):1943-9. PMC: 3372108. DOI: 10.1128/JCM.00487-12. View

20.

Liang T, Rehermann B, Seeff L, Hoofnagle J . Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med. 2000; 132(4):296-305. DOI: 10.7326/0003-4819-132-4-200002150-00008. View